Greetings. Welcome to TG Therapeutics Second Quarter 2021 Earnings Call and Business Update. [Operator Instructions]
At this time, I will now turn the conference over to Jenna Bosco, Senior Vice President of Corporate Communications. Jenna, you may now begin.
Jenna Bosco
Senior Vice President, Corporate Communications
Thank you. Welcome everyone and thanks for joining us this morning. I m Jenna Bosco and with me today to discuss the second quarter 2021 financial results and provide a business update are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer. Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments as well as an update on our current pivotal programs and remaining key goals for 2021. Adam will then provide an update on our commercialization efforts and Sean will provide a brief overview of our financial results, before
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Harmony Biosciences first-quarter 2021 financial update call. [Operator instructions] I would now like to hand the conference over to your host today, Lisa Caperelli, investor relations. Please go ahead.
Lisa Caperelli
Investor Relations
Thank you, operator. Good morning, everyone and thank you for joining us today as we review Harmony Biosciences first-quarter 2021 financial performance and provide business updates. Before we begin, I encourage everyone to go to the Investors section of the Harmony Biosciences website to find the press release and slides that accompany our presentation today, including a reconciliation of the GAAP to non-GAAP financial measures. At this stage of our company life cycle, we believe non-GAAP financial results better represent the underlying economics of our business.